Prostate cancer remains a significant global health concern. From well-established risk factors to regional healthcare disparities, understanding the geographical variations in prostate cancer rates sheds light on the complexities of this disease. The global prostate cancer therapeutics market is expected to reach $26.7 billion by 2031, driven by an aging population and innovative drugs extending survival rates for advanced cancer patients.